Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

12.44 -0.23 (-1.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nurix Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 Next >
Amazon To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
8 Analysts Have This To Say About Nurix Therapeutics
Via Benzinga
Decoding 9 Analyst Evaluations For Nurix Therapeutics
Via Benzinga
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts
Via Benzinga
Unveiling 6 Analyst Insights On Nurix Therapeutics
Via Benzinga
Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments
The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. 
Via Benzinga
Analyst Ratings For Nurix Therapeutics
Via Benzinga
Forecasting The Future: 13 Analyst Projections For Nurix Therapeutics
Via Benzinga
Analyst Scoreboard: 12 Ratings For Nurix Therapeutics
Via Benzinga
Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views
Via Benzinga
Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China. 
Via Benzinga
Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Nurix Therapeutics Stock
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Expert Outlook: Nurix Therapeutics Through The Eyes Of 14 Analysts
Via Benzinga
Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday
Via Benzinga
This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Nvidia’s Earnings Loom In The Summer Stock Snooze-Fest
To the casual observer, stocks look to be drifting around on a Lazy River ride, but the truth is, they’re consolidating their recent gains. This is actually bullish price action. 
Via Talk Markets
TJX To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Here Is What You Missed On Wall Street On Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Stock Market Weekly Review: Nvidia, AI Chip Plays Hit Resistance
The Nasdaq and S&P 500 backed off highs. The Dow regained a key level. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.